Advertisement
Canada markets open in 1 hour 3 minutes
  • S&P/TSX

    21,554.86
    -26.44 (-0.12%)
     
  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     
  • DOW

    39,150.33
    +15.53 (+0.04%)
     
  • CAD/USD

    0.7309
    +0.0006 (+0.08%)
     
  • CRUDE OIL

    80.88
    +0.15 (+0.19%)
     
  • Bitcoin CAD

    84,044.14
    -3,933.74 (-4.47%)
     
  • CMC Crypto 200

    1,265.91
    -43.81 (-3.34%)
     
  • GOLD FUTURES

    2,338.20
    +7.00 (+0.30%)
     
  • RUSSELL 2000

    2,022.03
    +4.64 (+0.23%)
     
  • 10-Yr Bond

    4.2570
    +0.0030 (+0.07%)
     
  • NASDAQ futures

    19,944.00
    -38.75 (-0.19%)
     
  • VOLATILITY

    13.80
    +0.60 (+4.54%)
     
  • FTSE

    8,274.78
    +37.06 (+0.45%)
     
  • NIKKEI 225

    38,804.65
    +208.18 (+0.54%)
     
  • CAD/EUR

    0.6808
    -0.0018 (-0.26%)
     

Biogen in up to $1.8 billion deal as rare diseases take center stage

Illustration shows Biogen logo

(Reuters) -Biogen said on Wednesday it had agreed to buy privately held Human Immunology Biosciences for up to $1.8 billion, bulking up on rare disease medicines as its older multiple sclerosis drugs face tepid demand due to rising competition.

Human Immunology's (HI-Bio) felzartamab has completed mid-stage studies for a type of kidney disease called primary membranous nephropathy, and in patients with a disease where the immune system makes antibodies that damage their transplanted organ.

The San Francisco-based company is also testing the therapy in patients with another chronic kidney disease known as IgA nephropathy. The therapy developer plans to conduct late-stage trials.

Since Christopher Viehbacher took the helm in late 2022, Biogen has acquired rare disease drugmaker Reata for $6.5 billion, abandoned its controversial Alzheimer's disease drug Aduhelm and cut jobs.

ADVERTISEMENT

The company is now counting on newer medicines such as a second approved Alzheimer's drug Leqembi, developed with Japanese partner Eisai, as well as Reata's Skyclarys to help drive growth.

The deal consists of $1.15 billion in upfront and up to $650 million in potential payments if felzartamab achieves certain development milestones.

The deal is expected to close in the third quarter, the companies said on Wednesday. HI-Bio is backed by investors such as biotech-focused ARCH Venture Partners and Monograph Capital.

(Reporting by Manas Mishra and Sriparna Roy in Bengaluru; Editing by Sriraj Kalluvila)